# Chapter 21: Radiation Oncology

## 21.1 Principles of Radiotherapy: Biological Effects on Cells

### 21.1.1 Mechanisms of Radiation-Induced Cellular Damage

Ionizing radiation damages the genetic material in cells through the generation of free radicals, which subsequently damage vital cellular components and lead to double-stranded DNA breaks (DSBs), resulting in chromosomal aberrations and rearrangements. The interaction of radiation with biological systems can be classified as either direct or indirect effects. 

**Direct Effects:**
Direct effects occur when radiation directly interacts with critical molecules such as DNA, causing immediate molecular damage through direct ionization or excitation. For direct damage to occur, the radiation must hit genetic material directly, but since the volume of sensitive genetic material is very small compared to the total cell volume, the probability of direct hits is relatively low.

**Indirect Effects:**
Indirect effects result from the interaction of radiation with water molecules, producing reactive free radicals (particularly hydroxyl radicals, OH•) that subsequently diffuse to and damage DNA. The OH• radical is believed to be the most effective of the reactive species in causing biological damage, as it can abstract hydrogen atoms from the deoxyribose moiety of DNA, yielding highly reactive DNA radicals.

### 21.1.2 DNA Damage and Repair Mechanisms

The cell nucleus is considered the primary target for important biological effects of radiation, with effects occurring as a direct result of DNA damage that has not been correctly restored by enzymatic repair processes. DNA undergoes spontaneous damage under normal cellular conditions, with thousands of random changes occurring daily from heat, metabolic accidents, and radiation exposure.

**Types of DNA Damage:**
- Single-strand breaks: More easily repaired using the intact complementary strand as a template
- Double-strand breaks: Potentially more dangerous as they leave no intact template strand for repair
- Chromosomal aberrations: Including deletions, translocations, and complex rearrangements

**Repair Mechanisms:**
Cells possess sophisticated DNA repair mechanisms including nonhomologous end-joining for double-strand breaks and various excision repair pathways for base damage. The importance of DNA repair is illustrated by diseases such as ataxia-telangiectasia (AT), where defects in the ATM protein lead to hypersensitivity to ionizing radiation and increased cancer risk.

### 21.1.3 Cellular Response to Radiation

Radiation can kill cells through two distinct mechanisms: apoptosis (programmed cell death) and reproductive failure (mitotic death).

**Apoptosis:**
Apoptotic cell death occurs within a few hours of irradiation, characterized by loss of normal nuclear structure and DNA fragmentation in a classical "laddering" pattern. The p53 tumor suppressor protein plays a crucial role in radiation-induced apoptosis, though p53-independent pathways involving Bcl-2/BAX also contribute.

**Reproductive Failure:**
Radiation can inhibit mitosis, causing cells to die during attempted cell division due to improperly repaired chromosomal damage. The fraction of cells blocked in the G₁/S checkpoint is reduced if cells are allowed to repair potentially lethal damage, demonstrating the importance of DNA repair in cell survival.

### 21.1.4 Bystander Effects

A significant phenomenon in radiation biology is the bystander effect, where cells that receive no direct radiation exposure exhibit biological effects similar to those occurring in directly irradiated cells. This phenomenon involves cell-to-cell communication via gap junctions and suggests that biological effects in cell populations may not be restricted to individual cell responses to DNA damage.

### 21.1.5 Factors Affecting Radiosensitivity

Tissues that undergo rapid cell growth and mitosis under normal conditions are most sensitive to radiation effects, while tissues with little cell growth (such as central nervous system, adrenal, and connective tissues) are more resistant. Radiosensitivity correlates with chromosome volume—cells with larger chromosomal material volumes demonstrate greater relative radiosensitivity.

**Cellular Factors:**
- Cell cycle phase (M and G₂ phases most sensitive)
- Oxygenation status (hypoxic cells are more radioresistant)
- DNA repair capacity
- Presence of radioprotective compounds

## 21.2 Types of Radiation Therapy

### 21.2.1 External Beam Radiation Therapy

External beam radiation therapy is applied externally through directed beams of radiation to treat cancer deep within the body. The goal of external beam radiation therapy is to deliver the prescribed amount of radiation to the targeted tumor while minimizing the amount received by surrounding normal tissues.

**Two-Dimensional Radiation Therapy (2D-RT):**
Prior to sophisticated computerized treatment planning, RT was planned using clinical information and conventional X-rays for field placement verification, resulting in large radiotherapy fields that assured tumor coverage but also caused limiting toxicity.

**Three-Dimensional Conformal Radiation Therapy (3D-CRT):**
With the introduction of computerized tomography scanners and treatment planning, radiation fields were shaped to correspond to tumors, resulting in less toxicity and the ability to escalate radiation dose with improved outcomes. 3D-CRT uses three-dimensional pictures of the cancer from CT or MRI scans, allowing more precise targeting and enabling higher doses while reducing damage to healthy tissue.

**Intensity-Modulated Radiation Therapy (IMRT):**
IMRT allows shaping of the radiation field to deposit higher doses to tumors while further sparing surrounding normal tissues. IMRT delivers conformal radiation to the target tumor by "crossing" multiple properly shaped beams of various intensities through paths that spare radiosensitive and critical adjacent tissues.

### 21.2.2 Brachytherapy

Brachytherapy is applied through the insertion of radiation-emitting sources directly within the tumor or adjacent body cavity. Brachytherapy is a radiotherapy technique where radioactive devices are inserted near tumors to safely deliver high doses of radiation to eliminate and shrink tumors.

**Types of Brachytherapy:**

**Low-Dose Rate (LDR) Brachytherapy:**
LDR brachytherapy dose rates are in the range of 0.4-2 Gy/hr, with delivery being continuous. Low-dose rate brachytherapy involves sources remaining in tissues for several days.

**High-Dose Rate (HDR) Brachytherapy:**
High-dose rate brachytherapy delivers a single dose of radiation within minutes using higher-activity sources that are electromechanically guided to tumors. HDR delivery occurs over several minutes with time gaps of hours to days between fractions.

**Clinical Applications:**
Brachytherapy is used extensively for prostate cancer, with biochemical control rates ranging from 85 to 97% at five years for low and intermediate-risk disease. For cervical cancer, brachytherapy is typically delivered as a boost with external beam radiotherapy for patients with Stage IB3-IVA disease.

### 21.2.3 Systemic Radiation Therapy

Radioisotope therapy is applied through the systemic injection of a radioisotope that has been designed to target specific tissues. Targeted radionuclide therapy uses molecules labeled with radionuclides to deliver toxic levels of radiation to disease sites, combining the specificity of cancer cell targeting with the known antitumor effects of ionizing radiation.

**Mechanisms:**
Unlike tumor-directed drugs that kill only directly targeted cells, radionuclides can exert a "bystander" or "crossfire" effect, potentially destroying adjacent tumor cells even if they lack the specific tumor-associated antigen or receptor.

**Clinical Applications:**
Common applications include treatment of thyroid cancer using radioactive iodine and palliation of pain from bone metastases using radioactive strontium. Advanced approaches include lutetium (177Lu) DOTA-TATE for targeting somatostatin-expressing neuroendocrine tumors.

## 21.3 Technological Advances in Radiotherapy

### 21.3.1 Intensity-Modulated Radiation Therapy (IMRT)

IMRT controls or modulates the radiation beam's intensity to make the radiation delivered more tightly conform with the 3D shape of the tumor. IMRT is a more complex form of radiation where the intensity of radiation is varied within each field, unlike conventional 3D-CRT which uses the same intensity throughout each beam.

**Advantages:**
Intensity modulation has permitted radiation oncologists to place sharper dose gradients across normal tissue structures, including bladder and rectum, with increased dose to tumor target, allowing higher doses with no additional clinical morbidity.

**Potential Concerns:**
IMRT has a higher integral radiation dose and increases the total volume of tissues exposed to radiation compared to conventional radiation therapy, which may theoretically translate to higher risk for secondary radiation-induced malignancies, especially in pediatric populations.

### 21.3.2 Stereotactic Body Radiation Therapy (SBRT)

SBRT is defined as an external beam radiation therapy method used to very precisely deliver a high dose of radiation to an extracranial target within the body, using either a single dose or a small number of fractions. SBRT combines multiple finely collimated radiation beams and stereotaxy (3D target localization), with multiple radiation beams intersecting to deliver an accurate, high dose of radiation to a carefully defined location.

**Technical Requirements:**
SBRT requires advanced patient positioning, patient immobilization, multi-leaf collimators (MLCs) and micro-MLCs, x-ray tracking (stereotactic), advanced control systems, and treatment planning software.

**Advantages:**
SBRT's most important features include the use of high-dose radiation delivered in one to five fractions within a few days, decreasing the overall length of treatment compared to standard fractionated radiotherapy which typically requires 25-50 fractions over 5-10 weeks.

**Clinical Applications:**
SBRT can be used as primary therapy for early-stage cancer or as targeted treatment for metastatic disease, with applications in lung/thorax, pancreas, liver, colon, kidney, and prostate tumors.

### 21.3.3 Proton Therapy

Charged particle radiotherapy uses beams of protons or other charged particles such as helium, carbon, or other ions instead of photons. Proton beam therapy uses protons rather than x-rays, and at high energy, protons can destroy cancer cells while depositing very little radiation dose beyond the tumor compared to x-rays.

**Physical Advantages:**
Charged particles have different depth-dose distributions compared to photons, with the ability to cover tumor areas using a single radiation field, achieving significant dose reduction to normal tissues beyond the target. The relative biological effectiveness (RBE) of protons is approximately 1.1 compared to conventional photon therapy.

**Advanced Techniques:**
Intensity modulated proton therapy (IMPT) uses a narrow proton beam that is "scanned" over the target volume by magnetic field while both the energy and intensity of the beam are modulated.

### 21.3.4 Image-Guided Radiation Therapy (IGRT)

Image-guided radiation therapy uses daily images of each treatment field to confirm patient positioning and ensure the target is in the field, allowing better tumor targeting and reduced damage to healthy tissue. In the past 10 years, X-ray and CT imaging capabilities have been added to treatment machines to allow therapists to guide radiation placement with increased precision and accuracy.

**Technologies:**
SBRT devices can use image guidance including kV or MV x-ray imaging, CT, or ultrasound to intermittently monitor the position of the targeted tumor by tracking bony structures or implanted fiducials.

## 21.4 Side Effects and Management

### 21.4.1 Classification of Radiation Effects

Side effects of radiotherapy are classified as acute (early), consequential, or late effects on normal tissues over time. Acute radiation toxicity is seen within a few weeks after treatment and usually involves intermitotic cells (skin and mucosa), while late complications emerge months to years after exposure and usually involve postmitotic cells (liver, kidney, heart, muscle, and bone).

**Acute Effects:**
Acute radiation damage predominantly involves rapidly proliferating cells, such as epithelial surfaces of the skin or digestive tract, manifesting when tissues are lost as part of normal cell turnover but there is inadequate replacement by damaged stem cells.

**Late Effects:**
Late complications occur in tissues with slow turnover, such as brain, kidney, liver, intestinal wall, subcutaneous tissue, and muscle, with consequences including fibrosis, atrophy, necrosis, and vascular damage.

### 21.4.2 Head and Neck Radiation Effects

**Skin and Mucosa:**
Acute responses include erythema, inflammation, desquamation, mucositis, pruritis, hypersensitivity, pain, and mucosal ulcers, with severe mucositis potentially requiring feeding tube placement. Late complications include alopecia, telangiectasia, fibrosis of masticator muscles resulting in trismus in 5-10% of patients, alterations in taste sensations, and dysphagia.

**Management:**
Management of severe mucositis includes scrupulous oral hygiene, topical analgesics, dietary modification, opioid analgesics, doxepin rinses, antacid+diphenhydramine mouthwash, mucoadhesive hydrogel, and enteral tube feeding in severe cases.

**Salivary Glands:**
Salivary gland irradiation may result in cell death by apoptosis, manifesting as swelling and tenderness after the first dose, progressing to xerostomia and subsequent severe dental caries and osteonecrosis. Management includes appropriate oral hygiene and dental care with fluoride treatment, chlorhexidine rinses, and regular dental follow-up.

### 21.4.3 Thoracic Radiation Effects

**Pulmonary Toxicity:**
Early phase effects include congestion, cough, dyspnea, fever, and chest pain caused by radiation pneumonitis, with radiographic infiltrates within the irradiated field. The natural course involves either gradual resolution or progression to chronic inflammation and fibrosis developing over months to years.

**Cardiac Toxicity:**
Radiation injury to the heart can manifest as acute pericarditis, pericardial effusion, constrictive pericarditis, valvular dysfunction, conductive system dysfunction, and myocardial fibrosis. Long-term effects manifest approximately ten years after treatment and contribute to high mortality in younger women diagnosed with breast cancer.

### 21.4.4 Abdominal and Pelvic Radiation Effects

**Gastrointestinal Toxicity:**
Acute toxicity presents as anorexia, nausea, vomiting, abdominal cramps, and diarrhea about 2-3 weeks after radiation therapy. Chronic effects include chronic diarrhea, malabsorption, recurrent bouts of ileus or obstruction, and proliferative mucosal telangiectasias or ulceration.

**Urinary Tract Effects:**
Radiation can cause varying degrees of bladder irritation, from mild dysuria, increased frequency, and urgency to urinary incontinence, gross hematuria, and bladder necrosis. Treatment is symptomatic with pain management, anticholinergics or antispasmodics, cranberry juice, hyperbaric oxygen, or surgical interventions for late complications.

**Reproductive Effects:**
Irradiation to ovaries leads to infertility or premature ovarian failure even at low doses, with increased sensitivity with advancing age. Patients undergoing radiotherapy should be offered sperm or egg cryopreservation options before treatment.

### 21.4.5 Secondary Malignancies

Radiation induces secondary malignancies with absolute risk ranging between 0.2% to 1% per year in cancer survivors after radiotherapy. There is a bimodal distribution: the first peak within three years is predominantly hematological malignancies like acute leukemias, while the second peak over ten years is driven primarily by solid malignancies.

**Common Secondary Malignancies by Primary Site:**
Hodgkin disease patients develop breast, lung, thyroid, and stomach cancers; breast cancer patients develop lung, leukemia, and opposite breast cancers; cervical cancer patients develop bladder, rectum, leukemia, and sarcomas.

### 21.4.6 Management Strategies

**Prevention and Risk Reduction:**
Techniques to reduce side effects include stereotactic surgery and SBRT for precise dose delivery, brachytherapy for localized treatment, appropriate fractionation schedules, and image-guided radiation therapy for precise targeting.

**Supportive Care:**
Coordination of care by surgical and medical oncologists, pathologists, radiotherapists, and interdisciplinary teams including oncology nurses, psychiatrists, nutritionists, and pain management services can significantly reduce toxicity and improve long-term quality of life.

**Risk Stratification:**
Identification of patients at higher risk includes those with active collagen vascular disease, inflammatory bowel disease, atherosclerotic vascular diseases, advanced age, and extreme BMI values.

### 21.4.7 Long-term Monitoring

Improved cure rates of all malignancies have resulted in more providers confronting patients with a wide range of chronic morbidities in long-term survivors, making awareness of common adverse effects essential for all healthcare providers.

**Surveillance Requirements:**
- Regular cardiovascular screening for thoracic radiation patients
- Pulmonary function monitoring for lung radiation
- Endocrine function assessment for head/neck radiation
- Secondary malignancy screening based on primary treatment site
- Functional assessment for organ-specific late effects

The comprehensive understanding of radiation biology, technological advances, and systematic management of side effects has transformed radiation oncology into a precise, effective treatment modality. RT is now recognized as an essential element of effective cancer care programs throughout the world, with the potential to improve cure rates of 3.5 million people and provide palliative relief for an additional 3.5 million people annually. Continued technological advancement and improved understanding of radiation biology will further enhance the therapeutic ratio, maximizing tumor control while minimizing normal tissue toxicity.
